EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Intuitive Surgical Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Intuitive Surgical Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The financial trajectory from 2021 to 2025 reflects a period of significant capital expansion and fluctuating economic value creation. While operational profitability has grown substantially over the long term, the company experienced a period of economic value destruction between 2022 and 2023, characterized by a capital charge that exceeded net operating profits.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT exhibited a volatile yet upward trend. After a contraction in 2022, where profits fell from 1,700,018 thousand to 1,187,823 thousand, a consistent recovery began. By 2025, NOPAT reached 2,976,548 thousand, representing a significant increase in operational earning power compared to the start of the period.
- Invested Capital and Cost of Capital
- Invested capital has grown steadily and aggressively, increasing from 4,517,800 thousand in 2021 to 11,374,500 thousand by 2025. This expansion indicates a heavy commitment to growth or infrastructure investment. Throughout this period, the cost of capital remained remarkably stable, hovering consistently around 25.6%, which served as a constant hurdle rate for all deployed capital.
- Economic Profit and Value Creation
- Economic profit transitioned through three distinct phases. Initial value creation in 2021 was followed by a two-year period of value destruction in 2022 and 2023, with the deficit peaking at -235,948 thousand. A return to value creation occurred in 2024 as NOPAT growth outpaced the capital charge. However, the substantial surge in invested capital in 2025 resulted in a diminished economic profit of 65,473 thousand, despite record-high NOPAT, suggesting that recent capital deployments have not yet yielded proportional operational returns.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in allowances.
3 Addition of increase (decrease) in deferred revenue.
4 Addition of increase (decrease) in equity equivalents to net income attributable to Intuitive Surgical, Inc..
5 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
6 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
7 Addition of after taxes interest expense to net income attributable to Intuitive Surgical, Inc..
8 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
9 Elimination of after taxes investment income.
Net income attributable to Intuitive Surgical, Inc. and Net Operating Profit After Taxes (NOPAT) both demonstrate fluctuating performance over the five-year period. While both metrics generally trend upwards, significant variations are observed, particularly in 2022.
- NOPAT Trend
- NOPAT experienced a notable decrease from US$1,700,018 thousand in 2021 to US$1,187,823 thousand in 2022, representing a substantial decline. A subsequent recovery is evident in 2023, with NOPAT reaching US$1,596,933 thousand. Continued growth is observed in 2024 and 2025, with NOPAT increasing to US$2,242,154 thousand and US$2,976,548 thousand respectively. This indicates a strong upward trajectory in recent years following the 2022 dip.
- Relationship between Net Income and NOPAT
- The values for Net Income and NOPAT are closely aligned throughout the period. The difference between the two metrics remains relatively consistent, suggesting minimal adjustments are being made between net income and operating profit after taxes. This consistency implies that non-operating items or accounting adjustments have a limited impact on the overall profitability picture.
- Growth Rates
- The largest percentage increase in NOPAT occurred between 2024 and 2025, with a growth rate of approximately 32.7%. The decline in 2022 represents the most significant percentage decrease in NOPAT over the observed period. The recovery from 2022 to 2023 shows a growth rate of approximately 34.4%.
Overall, the observed trends suggest a period of disruption in 2022 followed by a robust recovery and continued expansion in subsequent years. The strong correlation between net income and NOPAT indicates that core operating performance is the primary driver of overall profitability.
Cash Operating Taxes
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The reported income tax expense and cash operating taxes demonstrate distinct patterns over the five-year period. Income tax expense fluctuates, while cash operating taxes exhibit a more complex trend with an initial increase followed by stabilization and a slight decline.
- Income Tax Expense
- Income tax expense increased significantly from 2021 to 2022, rising from US$162.2 million to US$262.4 million. A substantial decrease was then observed in 2023, with expense falling to US$141.6 million. This was followed by increases in both 2024 and 2025, reaching US$336.3 million and US$434.8 million respectively. The overall trend indicates volatility, with a clear upward movement in the latter two years of the observed period.
- Cash Operating Taxes
- Cash operating taxes show a pronounced increase from 2021 to 2022, moving from US$226.7 million to US$448.3 million. The rate of increase slowed in 2023, with taxes reported at US$423.0 million. Values for 2024 and 2025 are US$472.97 million and US$417.4 million, respectively. While remaining relatively high, the 2025 figure represents a slight decrease from the 2024 level, suggesting a potential stabilization or minor reduction in cash tax outflows.
The difference between income tax expense and cash operating taxes is notable throughout the period. Cash operating taxes consistently exceed income tax expense, indicating the presence of timing differences or non-cash tax effects. The magnitude of this difference varies annually, potentially impacting the calculation of economic value added (EVA) and requiring further investigation into the underlying causes of these discrepancies.
- Relationship between Income Tax Expense and Cash Taxes
- The consistent difference between the two measures suggests the influence of deferred tax assets or liabilities. The larger cash tax payments relative to reported income tax expense could be due to factors such as accelerated depreciation for tax purposes, or the recognition of taxable temporary differences. Understanding these factors is crucial for accurate EVA calculation and financial performance assessment.
The observed trends in both income tax expense and cash operating taxes warrant continued monitoring to assess their impact on future financial performance and the company’s ability to generate economic value.
Invested Capital
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of allowance for doubtful accounts receivable.
4 Addition of deferred revenue.
5 Addition of equity equivalents to total Intuitive Surgical, Inc. stockholders’ equity.
6 Removal of accumulated other comprehensive income.
7 Subtraction of construction-in-process.
8 Subtraction of available-for-sale marketable securities.
The invested capital of the company demonstrates a consistent upward trend over the five-year period. Simultaneously, the composition of capital sources has shifted, with a notable increase in reported debt and leases alongside growth in stockholders’ equity.
- Invested Capital Trend
- Invested capital increased from US$4,517.8 million in 2021 to US$11,374.5 million in 2025. This represents a cumulative increase of 151.8% over the period. The growth rate appears to be accelerating, with larger absolute increases observed in the later years of the period, particularly between 2023 and 2025.
- Debt & Leases
- Total reported debt and leases exhibited an overall increasing trend. While a slight decrease was observed between 2022 and 2023, the amount rose significantly from US$87.0 million in 2021 to US$170.9 million in 2025, representing a 96.4% increase. The most substantial increase occurred between 2023 and 2024, jumping from US$89.8 million to US$146.0 million.
- Stockholders’ Equity
- Total stockholders’ equity also increased over the period, moving from US$11,901.1 million in 2021 to US$17,824.0 million in 2025, a 49.8% increase. There was a decrease between 2021 and 2022, but equity then increased consistently through 2025. The rate of increase in equity appears to be relatively stable compared to the more volatile changes in debt.
- Capital Structure Shift
- The relative contribution of debt to invested capital has increased. In 2021, debt and leases represented approximately 2.0% of invested capital. By 2025, this proportion had risen to approximately 1.5%. While the percentage appears small, the absolute increase in debt suggests a growing reliance on debt financing to fund growth, despite a larger overall increase in equity.
The observed trends suggest the company is actively investing in its operations and expansion, funded by a combination of debt and equity. The increasing reliance on debt warrants further investigation to assess associated financial risks and sustainability.
Cost of Capital
Intuitive Surgical Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Operating lease liability3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2025-12-31).
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Operating lease liability3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Operating lease liability3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Operating lease liability3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Operating lease liability3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
Economic Spread Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| Abbott Laboratories | ||||||
| Elevance Health Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial trajectory between 2021 and 2025 is characterized by significant capital expansion coupled with volatile economic value creation. While invested capital demonstrates a consistent upward trend, the economic spread ratio and resulting economic profit exhibit substantial fluctuations, indicating periods where the return on invested capital failed to exceed the cost of capital.
- Economic Spread Ratio Trends
- A sharp contraction is observed from 2021 to 2022, with the ratio falling from a peak of 12.03% to -3.58%. This negative spread persisted through 2023 at -3.30%, signaling that the company did not generate returns sufficient to cover its cost of capital during this biennium. A recovery occurred in 2024, with the ratio returning to a positive 3.15%, before declining again to 0.58% by 2025. This suggests a narrowing margin of value creation despite the overall growth in the business scale.
- Economic Profit Performance
- Economic profit mirrored the movements of the spread ratio, transitioning from a substantial surplus of US$ 543.69 million in 2021 to deficits of US$ 193.05 million in 2022 and US$ 235.95 million in 2023. The return to profitability in 2024 reached US$ 245.72 million, though this figure diminished to US$ 65.47 million by 2025. The volatility in these figures highlights an inconsistent ability to convert increased capital investments into economic value.
- Invested Capital Growth
- Invested capital grew monotonically over the five-year period, increasing from US$ 4.52 billion in 2021 to US$ 11.37 billion by 2025. This represents a significant expansion of the capital base. The divergence between the steady growth of invested capital and the fluctuating economic spread ratio indicates that capital deployment has not consistently yielded proportional increases in economic profit, leading to the observed compression of the spread ratio in the final year of the period.
Economic Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Revenue | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| Adjusted revenue | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| Abbott Laboratories | ||||||
| Elevance Health Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenue
= 100 × ÷ =
3 Click competitor name to see calculations.
The financial performance between 2021 and 2025 is characterized by a divergent trend between top-line growth and economic value creation. While revenue experienced consistent and substantial expansion, economic profit exhibited significant volatility, including a multi-year period of value destruction.
- Adjusted Revenue Growth
- A consistent upward trajectory is observed in adjusted revenue, which increased from 5.74 billion USD in 2021 to 10.14 billion USD by 2025. This steady growth indicates a continuous expansion of the operational scale throughout the analyzed period.
- Economic Profit Volatility
- Economic profit shifted from a positive 543.69 million USD in 2021 to negative values in 2022 (-193.05 million USD) and 2023 (-235.95 million USD). A recovery was recorded in 2024, with economic profit returning to positive territory at 245.72 million USD, before declining again to 65.47 million USD in 2025.
- Economic Profit Margin Analysis
- The economic profit margin mirrored the volatility of absolute economic profit, starting at 9.47% in 2021 and dropping to -3.09% in 2022 and -3.29% in 2023. Despite a rebound to 2.93% in 2024, the margin compressed sharply to 0.65% in 2025, indicating that the increase in revenue did not yield a proportional increase in economic value.
The data suggests a period of capital inefficiency between 2022 and 2023, during which the company failed to generate returns above its cost of capital. Although economic value creation resumed in 2024 and 2025, the significant margin compression observed in the final year—despite record-high revenue—points to a diminishing ability to translate scale into economic profit.